Clinical effect of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
Eva-Carina Heier,Florian Eyer,Christian Rabe,Stefanie Geith,Paul I Dargan,David M Wood,Fridtjof Heyerdahl,Alison M Dines,Isabelle Giraudon,Knut Erik Hovda,Chris Yates,Odd Martin Vallersnes,Òscar Miró,Matthias E Liechti,Tobias Zellner,Euro-DEN Research Group,Lukasz Anand,Wojciech Waldman,Kurt Anseeuw,Johan Gillebeert,Robertas Badaras,Gabija Laubner,Jeffrey Bonnici,Miran Brvar,Damjan Grenc,Rachel Burke,Adrian Moughty,Blazena Caganova,Miguel Galicia,Ketevan Gorozia,Soso Kutubidze,Karim Jaffal,Bruno Mégarbane,Gesche Jürgens,Jutta Konstari,Viesturs Liguts,Roberts Stašinskis,Cathelijne Lyphout,Ibolya Toth,Roberta Noseda,Alessandro Ceschi,Niall O'Connor,Radhika Sopirala,Raido Paasma,Juan Ortega Perez,Jordi Puiguriguer,Marius Perminas,Jonas Surkus,Per Sverre Persett,Kristiina Põld,Julia Radenkova-Saeva,Jan Rulisek,Federico Vigorita,W Stephen Waring,Sergej Zacharov,Yasmin Schmid,Evangelia Liakoni,Irene Scholz,Femke Mj Gesnigt,Maro H Sandel,Gabriela Viorela Nitescu,Feriyde Calýskan,Irma van den Hengel-Koot,Laura Hondebrink
DOI: https://doi.org/10.1097/MEJ.0000000000000932
2022-08-01
Abstract:Background and importance: Patients who use recreational drugs frequently co-ingest ethanol, which is considered a central nervous system (CNS) depressant. The clinical relevance of this in acute toxicity involving other CNS depressants is not well described. Objective: To assess the clinical impact of ethanol co-use in patients presenting to the emergency department (ED) with acute toxicity involving the use of CNS depressant drugs. Design, settings and participants: A retrospective multicentre study using data from the Euro-DEN Plus database from January 2014 to December 2019. Outcomes measure and analysis: Comparison of epidemiologic and clinical characteristics, ED and hospital management of patients with CNS depressant intoxication with or without ethanol co-use. Main results: Although 7644 (17.5%) of the 43 633 presentations were included, ethanol was co-ingested in 3811 (49.9%). In total 53.3% required medical treatment, 14 patients died. Patients with ethanol co-use more frequently presented with a Glasgow Coma Scale (GCS) ≤8 (34.1% vs. 22.4%; P < 0.001), vomiting (8.1% vs. 4.6%; P < 0.001), anxiety (12 % vs. 6.4%; P < 0.001), agitation/aggression (22% vs. 14.7%; P < 0.001), seizures (3.8% vs. 2.4%; P < 0.001) and hypotension (7.5% vs. 4.6%; P < 0.001). They more often required ambulance transport (85.5% vs. 76.5%; P < 0.001), medical treatment (57.3% vs. 48.0%; P < 0.001), hospitalization (27.7% vs. 18.9%; P < 0.001), and admission to intensive care (12.2% vs. 4.0%; P < 0.001). Subgroup analysis showed that GCS ≤8 was particularly common in patients who combined ethanol with opioids or gamma-hydroxybutyrate (GHB)/gamma-butyrolactone (GBL). Conclusion: Co-use of ethanol with CNS-depressant drugs appears to increase the risk of adverse effects and is associated with a higher need for medical treatment, especially when ethanol is combined with opioids or GHB/GBL.